Ongoing Clinical Trials for Polyneuropathy
Currently, there is 1 ongoing clinical trial investigating treatments for polyneuropathy, specifically focused on chemotherapy-induced polyneuropathy in cancer patients. This trial is exploring the use of a topical oil treatment to prevent and reduce nerve damage symptoms caused by certain chemotherapy medications.
Clinical trial locations
Study on Aconite Pain Oil to Prevent and Reduce Symptoms of Chemotherapy-Induced Polyneuropathy in Cancer Patients
This clinical trial is investigating whether Aconite Pain Oil, also known as Aconit Schmerzöl, can help prevent or reduce nerve damage that sometimes occurs as a side effect of chemotherapy treatment. This type of nerve damage, called chemotherapy-induced polyneuropathy, can cause uncomfortable symptoms such as pain, tingling, and numbness, particularly in the hands and feet.
Who can participate:
- Adults aged 18 years or older
- Patients with solid tumors who are scheduled to receive chemotherapy with taxanes or platinum derivatives for at least 3 months
- Patients with a Karnofsky Index of 70% or higher, meaning they can care for themselves even if they may not be able to do all normal activities
- Patients with an expected life expectancy of at least 12 months
- Women of childbearing age must have a negative pregnancy test
- A fully signed consent form from both the patient and the investigator is required
Who cannot participate:
- Patients currently receiving or who have recently received other treatments that might interfere with the study
- Patients with a history of severe allergic reactions to any of the study medications
- Patients with other serious health conditions that could affect their safety or the study results
- Pregnant or breastfeeding women
- Patients unable to follow study procedures or attend required visits
- Patients who have recently participated in another clinical trial
What the trial involves:
The main goal of this study is to determine whether Aconite Pain Oil can effectively reduce the risk of developing moderate to severe nerve damage during chemotherapy. Researchers aim to achieve a 35% reduction in the risk of developing grade II or higher nerve damage compared to patients receiving a placebo.
Participants will apply the oil topically to their skin as part of their routine cancer care. Throughout the trial, which is expected to continue until August 2027, the research team will carefully monitor the occurrence and severity of nerve damage symptoms. They will also assess various sensory functions including temperature sensation, touch perception, and pain responses, as well as motor skills, reflexes, and overall patient satisfaction with the treatment.
Investigational treatment:
Aconite Pain Oil is a topical treatment applied directly to the skin. It is believed to work by modulating nerve signals and reducing inflammation, though the exact mechanism is still being studied. The trial will compare its effectiveness against a placebo to determine whether it can genuinely help prevent or reduce the uncomfortable nerve damage symptoms that can affect quality of life during cancer treatment.
Summary
Currently, only one clinical trial is actively recruiting patients with polyneuropathy, specifically those experiencing or at risk of developing chemotherapy-induced nerve damage. This trial is being conducted in Germany and focuses on evaluating a topical oil treatment as a potential preventive measure. The study represents an important effort to find practical solutions for managing one of the challenging side effects of cancer treatment, with the potential to improve quality of life for patients undergoing chemotherapy with taxanes and platinum-based drugs.
